DAUICE TURNER: Open Payments
NPI 1336517887 · ANDOVER, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,717 in 103 payments from 23 companies in 2025. Trend: 2023 $23 · 2024 $404 · 2025 $1,717
Food & beverage: $1,717
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $296 |
| Lilly USA, LLC | 12 | $211 |
| Amgen Inc. | 13 | $173 |
| ABBVIE INC. | 15 | $162 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $149 |
| Novo Nordisk Inc | 7 | $122 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Sumitomo Pharma America, Inc. | 3 | $60 |
| Astellas Pharma US Inc | 3 | $55 |
Products named: FARXIGA, Kerendia, MOUNJARO, AIRSUPRA, QULIPTA, Wegovy, REXULTI, XIFAXAN.
Industry payments across KS — which companies pay providers there.
